| Authors: |
Phillips JE; Hoffmann-La Roche, pRED, Pharma Research & Early Development, DTA Inflammation, 340 Kingsland Street, Nutley, NJ, 07110, USA. Electronic address: Jonathan.phillips@amgen.com., Peng R; Hoffmann-La Roche, pRED, Pharma Research & Early Development, DTA Inflammation, 340 Kingsland Street, Nutley, NJ, 07110, USA., Burns L; Hoffmann-La Roche, pRED, Pharma Research & Early Development, DTA Inflammation, 340 Kingsland Street, Nutley, NJ, 07110, USA., Harris P; Hoffmann-La Roche, pRED, Pharma Research & Early Development, DTA Inflammation, 340 Kingsland Street, Nutley, NJ, 07110, USA., Garrido R; Hoffmann-La Roche, pRED, Pharma Research & Early Development, DTA Inflammation, 340 Kingsland Street, Nutley, NJ, 07110, USA., Tyagi G; Hoffmann-La Roche, pRED, Pharma Research & Early Development, DTA Inflammation, 340 Kingsland Street, Nutley, NJ, 07110, USA., Fine JS; Hoffmann-La Roche, pRED, Pharma Research & Early Development, DTA Inflammation, 340 Kingsland Street, Nutley, NJ, 07110, USA., Stevenson CS; Hoffmann-La Roche, pRED, Pharma Research & Early Development, DTA Inflammation, 340 Kingsland Street, Nutley, NJ, 07110, USA. |